GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SanBio Co Ltd (TSE:4592) » Definitions » ROE % Adjusted to Book Value

SanBio Co (TSE:4592) ROE % Adjusted to Book Value : -9.47% (As of Jan. 2024)


View and export this data going back to 2015. Start your Free Trial

What is SanBio Co ROE % Adjusted to Book Value?

SanBio Co's ROE % for the quarter that ended in Jan. 2024 was -130.41%. SanBio Co's PB Ratio for the quarter that ended in Jan. 2024 was 13.77. SanBio Co's ROE % Adjusted to Book Value for the quarter that ended in Jan. 2024 was -9.47%.


SanBio Co ROE % Adjusted to Book Value Historical Data

The historical data trend for SanBio Co's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SanBio Co ROE % Adjusted to Book Value Chart

SanBio Co Annual Data
Trend Jan15 Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.79 -3.46 -3.27 -15.99 -5.32

SanBio Co Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -46.36 -5.73 -8.76 -1.27 -9.47

Competitive Comparison of SanBio Co's ROE % Adjusted to Book Value

For the Biotechnology subindustry, SanBio Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SanBio Co's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SanBio Co's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where SanBio Co's ROE % Adjusted to Book Value falls into.



SanBio Co ROE % Adjusted to Book Value Calculation

SanBio Co's ROE % Adjusted to Book Value for the fiscal year that ended in Jan. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-73.24% / 13.77
=-5.32%

SanBio Co's ROE % Adjusted to Book Value for the quarter that ended in Jan. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-130.41% / 13.77
=-9.47%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SanBio Co ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of SanBio Co's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


SanBio Co (TSE:4592) Business Description

Industry
Traded in Other Exchanges
Address
8-1 Street Luke Tower 32nd Floor, Akashi-cho, Chuo-ku, Tokyo, JPN, 104-0044
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.

SanBio Co (TSE:4592) Headlines

No Headlines